名媛直播

Ian Ingram

Ian Ingram

Authors >

Ian Ingram

Ian Ingram joined 名媛直播 in 2018 as Deputy Managing Editor, and covers oncology for the site. Ian Ingram has been a medical editor for the past decade. Prior to joining 名媛直播, he was managing editor of Cancer Network, directing the website鈥檚 news coverage and video production. Ian has also worked as a fact-checker, was an assistant editor at Narrative Magazine, and a manuscript reader at the Paris Review. He holds a B.A. in journalism from Purchase College. Ian lives in Connecticut, enjoys tennis, and almost always bowls a perfect game.

Connect:

email image

Latest from Ian Ingram

ASH over a photo of San Diego Convention Center.

Completely Oral Regimen Effective, Feasible in APL

97% of patients alive and relapse-free at 3 years

FDA APPROVED pirtobrutinib (Jaypirca) over a computer rendering of chronic lymphocytic leukemia cells.

Non-Covalent BTK Inhibitor Approved for CLL

Response rates with pirtobrutinib reached 72% in heavily pretreated patient population

A computer rendering of a transparent body with the pancreas highlighted.

Two Approaches for Infected Necrotizing Pancreatitis Go Head-to-Head

Upfront endoscopic necrosectomy wins out on reinterventions, time to clinical improvement

A photo of bottles of fluvoxamine tablets.

Higher-Dose Fluvoxamine Fails for COVID Outpatients

Recovery time with 100-mg dose no different than placebo

FDA MARKETING Diagnostic test for chlamydia and gonorrhea with at-home sample collection (Simple 2 Test) over the product.

First At-Home Test for Chlamydia and Gonorrhea Authorized by FDA

OTC option arrives amid rising cases of the sexually transmitted infections

A photo of the vial and packaging of Aliqopa.

Lymphoma Drug Copanlisib to Be Pulled From U.S. Market

Failed confirmatory trial takes down another PI3K inhibitor

FDA APPROVED Chikungunya vaccine (Ixchiq) over a transmission electron microscope image of chikungunya viruses.

First Chikungunya Vaccine Lands Conditional FDA Approval

High level of seroprotection, but adverse reactions warrant postmarketing study

FDA APPROVED fruquintinib (Fruzaqla) over a computer rendering of colorectal cancer.

New Oral Drug Approved for Metastatic Colorectal Cancer

In phase III trials of pretreated patients, fruquintinib improved survival versus placebo

FDA approved vonoprazan (Voquezna) over a computer rendering of pills traveling down an inflamed esophagus.

New Option Approved for Erosive Esophagitis

Vonoprazan lands indication for healing and maintenance across all grades of condition

ESMO over a photo of IFEMA Madrid in Spain.

New Options Challenge Standard Treatments in EGFR-Mutant NSCLC

Amivantamab-based regimens improved oncologic outcomes, but with more side effects

鈥�

9

鈥�